Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases

Gubert, Fernanda; J, da Silva; Vasques, Juliana Ferreira; Gonçalves, Renata Guedes de Jesus; Martins, Robertta Silva; Sá, Mauro Paes Leme de; Mendez-Otero, Rosália; Zapata‐Sudo, Gisele

doi:10.3390/ijms22147447

Cited by 25 publications

(19 citation statements)

References 141 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On injured pancreatic islets, beneficial effects are consequent to the immunomodulatory, anti-inflammatory and anti-apoptotic actions of the molecules secreted by MSCs, which protect endogenous β-cells, stimulate their regeneration and proliferation and ameliorate insulin resistance, reversing hyperglycemia, the main determinant of DCM [ 102 ]. Regarding cardiac repair, MSCs have protective and regenerative effects in several types of cardiovascular diseases [ 103 ]. They can differentiate into cardiomyocytes, endothelial cells and vascular smooth muscle cells [ 104 ], but, again, rather than cellular replacement, tissue repair seems mainly related to MSCs’ secretome, through which they suppress inflammatory responses and induce neovascularization, resulting in cardiac tissue preservation [ 105 ].…”

Section: Preclinical and Clinical Approaches To Msc In Diabetes-induced Cardiac Complicationsmentioning

confidence: 99%

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

Gonçalves

Vasques

et al. 2022

Cells

Self Cite

View full text Add to dashboard Cite

The incidence and prevalence of diabetes mellitus (DM) are increasing worldwide, and the resulting cardiac complications are the leading cause of death. Among these complications is diabetes-induced cardiomyopathy (DCM), which is the consequence of a pro-inflammatory condition, oxidative stress and fibrosis caused by hyperglycemia. Cardiac remodeling will lead to an imbalance in cell survival and death, which can promote cardiac dysfunction. Since the conventional treatment of DM generally does not address the prevention of cardiac remodeling, it is important to develop new alternatives for the treatment of cardiovascular complications induced by DM. Thus, therapy with mesenchymal stem cells has been shown to be a promising approach for the prevention of DCM because of their anti-apoptotic, anti-fibrotic and anti-inflammatory effects, which could improve cardiac function in patients with DM.

show abstract

Section: Preclinical and Clinical Approaches To Msc In Diabetes-induced Cardiac Complicationsmentioning

confidence: 99%

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

Gonçalves

Vasques

et al. 2022

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…On the other hand, there have been numerous clinical trials that recently proposed MSCs as a promising therapeutic agent to treat several diabetic complications, including DCM [5,6] . Orlic et al [18] demonstrated that locally delivered autologous BM-MSCs to mice with infarcted hearts could result in regeneration of damaged myocardium.…”

Section: Discussionmentioning

confidence: 99%

“…In recent decades, from a therapeutic perspective and facilitated by the ease of preparation and immunologic privilege, multipotent mesenchymal stem cells (MSCs) have been used systemically or locally as an extremely promising therapeutic agent to treat various diseases, including diabetes complications and heart diseases [1,5] . Therefore, MSCs transplantation has been widely used as an effective method of protecting the damaged myocardium and improving cardiac function in many nonischemic or ischemic heart diseases, since they can migrate to injured cardiac sites and regenerate heart tissues by paracrine mediators that could alleviate the established DCM by supporting other cells' nutrition and environment [6] . MSCs were found to possess wide repertoires of growth factors including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and some cytokines/chemokines.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ameliorating Effects of Mesenchymal Stem Cells Drived From Adipose and Bone Marrow Tissues on Cardiomyopathy of Diabetic Rats: A Comparative Stud

El-Sawah

El-Hallous

Khalil

et al. 2022

Egyptian Journal of Zoology

View full text Add to dashboard Cite

Diabetic cardiomyopathy (DCM) is considered one of the main diabetic complications, contributing to specific forms of heart failure independent from hypertension or ischemia. There are increased research efforts to further explore a new potential therapeutic strategy for preventing or reversing DCM progression. The present research aimed to explore which type of stem cell-based therapies could serve as an effective tool for the treatment of DCM in type 1 diabetic rats. Four groups of male Wistar rats have been used in this study including the control group, a diabetic-untreated group, and two diabetic rat groups treated with either mesenchymal stem cells (MSCs) derived from adipose tissue (AD-MSCs) or bone marrow (BM-MSCs). Interestingly, serum levels of heart dysfunction markers (LDH and CK-MB) in the diabetic rats were found to be declined to near-normal levels following injection with either of the two MSCs types. Also, BM-MSCs or AD-MSCs (1×10 6 cell/rat)-treated diabetic rats exhibited significant decreases in the cardiac xanthine oxidase activity, reactive oxygen species, and malondialdehyde level, accompanied with marked elevations in various antioxidants, compared with the diabetic untreated group. The results also clearly point out the excellence of AD-MSCs injection as a potential agent in alleviating the DCM over BM-MSCs injection.

show abstract

“…Instead, the mechanisms underlying their beneficial effects in vivo are rather related to their paracrine activity [ 21 , 22 , 23 , 24 ]. MSCs have the ability to secrete various bioactive molecules, including cytokines, chemokines, growth factors, microRNAs (miRs), and extracellular vesicles (EVs), that have positive effects on failing hearts by attenuating the degree of cardiac fibrosis [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

Hopes and Hurdles of Employing Mesenchymal Stromal Cells in the Treatment of Cardiac Fibrosis

Neuber

Emmert

Nazari-Shafti

2021

IJMS

View full text Add to dashboard Cite

Excessive cardiac fibrosis plays a crucial role in almost all types of heart disease. Generally, cardiac fibrosis is a scarring process triggered in response to stress, injury, or aging and is characterized by the accumulation of activated myofibroblasts that deposit high levels of extracellular matrix proteins in the myocardium. While it is beneficial for cardiac repair in the short term, it can also result in pathological remodeling, tissue stiffening, and cardiac dysfunction, contributing to the progression of heart failure, arrhythmia, and sudden cardiac death. Despite its high prevalence, there is a lack of effective and safe therapies that specifically target myofibroblasts to inhibit or even reverse pathological cardiac fibrosis. In the past few decades, cell therapy has been under continuous evaluation as a potential treatment strategy, and several studies have shown that transplantation of mesenchymal stromal cells (MSCs) can reduce cardiac fibrosis and improve heart function. Mechanistically, it is believed that the heart benefits from MSC therapy by stimulating innate anti-fibrotic and regenerative reactions. The mechanisms of action include paracrine signaling and cell-to-cell interactions. In this review, we provide an overview of the anti-fibrotic properties of MSCs and approaches to enhance them and discuss future directions of MSCs for the treatment of cardiac fibrosis.

show abstract

Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases

Cited by 25 publications

References 141 publications

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

Ameliorating Effects of Mesenchymal Stem Cells Drived From Adipose and Bone Marrow Tissues on Cardiomyopathy of Diabetic Rats: A Comparative Stud

Hopes and Hurdles of Employing Mesenchymal Stromal Cells in the Treatment of Cardiac Fibrosis

Contact Info

Product

Resources

About